Focus products
Please click on a turquoise country to see the national focus products.
Focus products
Partner countries have identified clinically important antibiotics and veterinary vaccines with a national vulnerable supply. The selection of these products is based on an assessment of national clinical needs, availability, and resistance patterns, informed by consultations with relevant stakeholders and data analysis. The list of focus products may be updated as the project advances.
Please click on a turquoise country to see the national focus products.
France
Amoxicillin, clavulanic acid (human)
Aztreonam (human)
Benzathine benzylpenicillin (human)
Cefixime (human)
Fosfomycin (human)
Phenoxymethylpenicillin (human)
Rifampicin (human)
Rifampicin, isoniazid (human)
Rifampicin, isoniazid, pyrazinamide (human)
Rifapentine (human)
Sulfamethoxazole, trimethoprim (human)
Vaccine for turkey rhinotracheitis virus (Veterinary)
Vaccine for clostridium related diseases in ruminant (Veterinary)
Vaccines for Muscovy ducks against Derszy disease ± parvovirosis (Veterinary)
Spain
Amikacin (human)
Aztreonam (human)
Benzathine phenoxymethylpenicillin (human)
Cefadroxil (human)
Sulfamethoxazole, trimethoprim (human)
Oxytetracycline (veterinary)
Vaccines for hemorrahagic enteritis in turkeys (veterinary)
Vaccines for respiratory disease complex in cattle/sheep/goats (veterinary)
Vaccines for coccidiosis (veterinary)
Belgium
Cefadroxil OR Cefalexin (human)
Daptomycin (human)
Phenoxymethylpenicillin (human)
Procaine-benzylpenicillin OR Benzathine Benzylpenicillin (human)
Rifampicin (human)
Sulfadiazine, trimethoprim (human)
Sulfamethoxazole, trimethoprim (human)
Thiamphenicol (human)
Amoxicillin (veterinary)
Ampicillin (veterinary)
Cefalexin (veterinary)
Dihydrostreptomycine (veterinary)
Doxycycline (veterinary)
Neomycin (veterinary)
Trimetoprim, sulfadimethoxine (veterinary)
Trimetoprim, sulfadimidine (veterinary)
Bulgaria
Amphotericin B “liposomal” (human)
Benzylpenicillin (human)
Ceftaroline (human pediatric only)
Daptomycin (human)
Eravacycline (human)
Erythromycin (human)
Fosfomycin (human)
Nitrofurantoin (human)
Phenoxymethylpenicillin (human)
Tobramycin (human)
Denmark
Flucloxacillin (human, pediatric)
Fosfomycin (human)
Nitrofurantoin (human)
Pivmecillinam (human)
Ampicillin (human and veterinay)
Benzylpenicillin (/procaine benzylpenicillin) (human and veterinary)
Gentamicin (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Rifampicin (human and veterinary)
Amoxicillin (veterinary)
Fucidic acid (veterinary)
Sulfadiazine, Trimethoprim (veterinary)
Finland
Amoxicillin (Human)
Benzylpenicillin sodium (Human)
Nitrofurantoin (Human)
Phenoxymethylpenicillin (Human)
Rifampicin (Human)
Cloxacillin (veterinary)
ERM vaccine for fish (veterinary)
Gentamicin (veterinary)
Phenoxymethylpenicillin (veterinary)
Procaine benzylpenicillin (veterinary)
Trimethoprim, Sulfonamide (veterinary)
Iceland
Amoxicillin (human and veterinary)
Amoxicillin and beta-lactamase inhibitor (human and veterinary)
Benzylpenicillin / Procaine benzylpenicillin (human and veterinary)
Cefalexin (human and veterinary)
Dicloxacillin (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Sulfamethoxazole, trimethoprim (human and veterinary)
Sulfadiazine, trimethoprim (human and veterinary)
Clindamycin (veterinary)
Enrofloxacinum (veterinary)
Oxytetracycline ( veterinary)
Italy
Amikacin (human)
Azithromycin (human)
Benzathine benzylpenicillin (human)
Chloramphenicol (human)
Clarithromycin (human)
Piperacillin, tazobactam (human)
Netherlands
Amoxicillin (Human)
Amoxicillin, clavuanic acid (Human)
Benzathine benzylpenicillin (Human)
Benzylpenicillin (Human)
Cefazolin (Human)
Ceftazidim (Human)
Ciprofloxacin (Human)
Clindamycin (Human)
Doxycycline (Human)
Metronidazole (Human)
Phenoxymethylpenicillin (Human)
Rifampicin (Human)
Sulfamethoxazole, trimethoprim (human)
Innovative vaccines against emerging and novel animal diseases (veterinary)
Norway
Benzylpenicillin (human)
Dicloxacillin (human)
Doxycycline (human)
Erythromycin or clarithromycin (human)
Flucloxacillin (human)
Gentamicin (human)
Phenoxymethylpenicillin (human)
Pivmecillinam (human)
TB antibiotics from WHO guidelines (human)
Procaine benzylpenicillin (veterinary)
Salmon vaccines (veterinary)
Poland
Azithromycin (Human)
Aztreonam (Human)
Benzathine benzylpenicillin (Human)
Benzylpenicillin sodium (Human)
Cefalexin (Human)
Flucloxacillin (Human)
Minocycline (Human)
TB antibiotics from WHO guidelines (Human)
Slovenia
Amoxicillin (human)
Cefuroxime (human)
Clarithromycin (human)
Flucloxacillin (human)
Gentamicin (human and veterinary)
Phenoxymethylpenicillin (human)
Tuberculosis antibiotics (human)
Vaccination for dengue (human)
Vaccine for erysipelothrix (Veterinary)
Sweden
Amoxicillin (human)
Ceftibuten (human)
Cefixime (human)
Colistin (human)
Phenoxymethylpenicillin (human)
Procaine benzylpenicillin (veterinary)
Rifampicin (human)
Sulfamethoxazole, trimethoprim (human)
Temocillin (human)
Trimethoprim, sulfadiazine (veterinary)
Malta
Amoxicillin (human)
Aztreonam (human)
Cefalexin (human)
Cefazolin (human)
Clindamycin (human)
Co-trimoxazole (human)
Fosfomycin (human)
Temocillin (human)
Oxytetracycline (Veterinary)
Vaccine for bovine parainfluenza virus, bovine respiratory syncytial virus and pasteurella (Veterinary)
Vaccine for bovine rotavirus, bovine coronavirus and escherichia (Veterinary)
Greece
Aztreonam (human)
Tobramycin (human)
*Greece joined the Access work package after the project start and thus may have fewer focus products
Latvia
Aztreonam (Human)
Daptomycin (Human)
Fosfomycin (Human)
Phenoxymethylpenicillin (Human)
Pivmecillinam (Human)
TB antibiotics from WHO guideline (Human)
*Latvia joined the Access work package after the project start and thus may have fewer focus products
Antibiotic assessment guide
Here you find the methodology that was applied by the countries to identify their focus products for human use (the veterinary methodology will be added here shortly).
Barriers to access
Participating countries have finalized an analysis of the national barriers impacting sustainable and reliable access to each of their focus products. Through collaboration with key stakeholders and data-driven assessments, the analysis uncovered actionable barriers across economic, regulatory, and supply chain dimensions.
This stakeholder-inclusive and granular approach has generated unprecedented insights into the unique factors influencing national availability to the focus products.
Barrier analysis guide
Here, you find the guide that was used by the countries to analyse the national barriers to sustainable and reliable access to their focus products.
Barrier analysis overview
Here, you find an overview document summarizing the key barriers identified in the barrier analysis.
Targeted interventions
Based on the results from the barrier analyses, participating countries are now prioritizing and tailoring concrete interventions at the national, regional, and European levels to improve access to their national focus products. The main focus from now on is to work on implementation of these targeted interventions.